1.Expression of Yes-associated protein and analysis of risk factors in differentiated thyroid carcinoma
Jianfeng ZENG ; Yuechao YANG ; Hong GUO ; Yatao WU ; Yuxiong LIU ; Jing LU ; Zhencheng JI
Chinese Journal of Endemiology 2014;(4):379-382
Objective To analyze the expression of Yes-associated protein and risk factors in differentiated thyroid carcinoma. Methods Clinical data of 152 patients with differentiated thyroid carcinoma and 27 cases of benign thyroid tumor from Changji Hui Autonomous Prefecture People’s Hospital of Xinjiang, were analyzed retrospectively. According to the expression levels of Yes-associated protein in differentiated thyroid cancer and benign thyroid tumor, univariate Chi-square test and multivariate Logistic regression methods were used to analyze the relationship between Yes-associated protein and gender, age, thyroid stimulating hormone(TSH) level, nodule size, capsule integrity, histological type and lymph node metastasis, in order to find out risk factors in differentiated thyroid cancer. Results The positive rate of expressed Yes-associated protein in benign thyroid tumor group was 66.7%(18/27), which was significantly higher than 31.58%(48/152) of differentiated thyroid cancer group, and the difference was statistically significant(χ2=12.127, P<0.01). Under an optical microscope, changes of Yes-associated protein were found to be mainly located in the nucleus and cytoplasm , and in benign thyriod tumor the degree of staining was deep, strong positive or moderately positive; differentiated thyroid carcinoma was lightly stained or no staining, weakly positive or negative. Chi-square test showed that the expression of Yes-associated protein was not affected by sex, age and pathological type(χ2= 0.419, 0.221, 0.315, all P >0.05); TSH level, nodule size, capsule integrity, lymph node metastasis had an impact on the expression of Yes-associated protein which was down regulated (χ2=4.020, 8.424, 4.386, 6.673, P<0.05 or<0.01). Logistic regression analysis showed that the nodule size was not a risk factor ( odds ratio , OR ) of Yes-associated protein expression (OR=1.929, P>0.05); TSH levels above 4.5 mU/L, lymph node metastasis and envelope incomplete were risk factors that down regulated the expression of Yes-associated protein (OR=2.167, 2.665, 3.048, all P<0.05). Conclusion Yes-associated protein is down regulated in differentiated thyroid cancer. Elevated TSH levels , incomplete capsule and lymph node metastasis are risk factors of Yes-associated protein down expression and differentiated thyroid cancer.
2.Application of wavelet analysis in pick-up of breath signal from oscillations in chest wall.
Journal of Biomedical Engineering 2012;29(1):65-69
In order to pick up breath signal from correlated noise background of the pulse of heart and artery etc, an algorithm based on wavelet de-noising has been introduced. With wavelet db4, the raw signal was decomposed into the scale space of six layers; threshold treatment was done with the self-adaptive threshold created by Stein's Unbiased Risk Estimate; then the wavelet coefficients were reconstructed. The result showed that the noise was significantly depressed.
Algorithms
;
Artifacts
;
Chest Wall Oscillation
;
methods
;
Humans
;
Monitoring, Physiologic
;
instrumentation
;
methods
;
Respiration
;
Respiratory Sounds
;
Signal Processing, Computer-Assisted
;
Wavelet Analysis
3.Research progress of oncolytic herpes simplex virus in the treatment of glioma
Haijun YANG ; Yatao WANG ; Maohua ZHENG
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care 2023;30(6):760-764
Glioma is a highly aggressive malignant tumor of the central nervous system that necessitates active treatment through surgery,radiotherapy,and chemotherapy.However,the prognosis of high-grade gliomas[World Health Organization(WHO)classification of central nervous system tumorsgrade Ⅲ-Ⅳ]remains poor,thus new treatment strategies are urgently needed.Oncolytic virus(OV)therapy is a kind of immunotherapy that can specifically infect and effectively kill tumor cells while activating anti-tumor immunity.The oncolytic herpes simplex virus(oHSV)is expected to emerge as a new adjuvant treatment for glioma due to its unique advantages.This article reviews the current understanding of oHSV,the anti-tumor mechanism of OV,the current clinical research status of oHSV targeted therapy for glioma,the research progress of oHSV collaborative anti-tumor strategy,and the existing problems in oHSV anti-glioma research,aiming to provide valuable insights for the treatment of glioma.